Abstract:OBJECTIVE:To observe the prevention and treatment of acute graft-versus-host disease (aGVHD) by murine marrow mesenchymal stem cells (MSCs) in vivo.METHODS:Allogeneic aGVHD model was established with lethally irradiated BALB/c recipients receiving allogeneic BM (BMC) and spleen cells (SP) from C57BL/6 with or without mMSCs at different dose and different time posttransplantation. Six groups were set up, group 1 (irradiation control group); group 2 (i.v. BMC only); group 3 (i.v. SP+ BMC); group 4 (i.v. SP + BMC + 1 x 10(5) mMSC at day 0); group 5 (i.v. SP + BMC +5 x 10(5) mMSC at day 0); group 6 (i.v. SP + BMC +1 x 10(5) mMSC at day 7). The survival was monitored daily. mMSCs infected with adenoviral vector (Ad-GFP) were injected into aGVHD model to observe the distribution of MSCs in vivo.RESULTS:(1) Addition of donor mMSCs significantly controlled the lethal GVHD. The survival time (day) in group 1 was 13.5 +/- 2.6, group 3 11.1 +/- 4.0, group 4 26.4 +/- 7.7, group 5 22.7 +/- 9.2, group 6 22.9 +/- 8.2, respectively. The difference between groups 4-6 and group 3 was statistically significant (P < 0.01), but there was no difference among groups 4-6 (P = 0.28); There was less lymphocyte infiltration and architectural disruption in the intestine and spleen of groups 4-6 than that of group 3; (2) mMSCs significantly reduced IFN-gamma and TNF-alpha in the serum of recipient mouse; the levels of IFN-gamma in groups 3, 4, 5, 6 were (607.9 +/- 157.1), (143.6 +/- 37.5), (117.0 +/- 77.8), (131.4 +/- 63.4) ng/L, respectively. And of TNF-alpha were (52.31 +/- 17.95), (6.02 +/- 3.99), (5.21 +/- 0.28), (22.39 +/- 18.21) ng/L, respectively. mMSCs had no effect on allogeneic T cell proliferation in GVHD model but increased apoptosis of allogeneic T cells. The percentage of CD3(+) Annexin V(+)PI(-) in each group were (10.3 +/- 6.6)%, (13.5 +/- 13.8)%, (19.7 +/- 6.0)%, (16.6 +/- 7.3)%, respectively. (3) After intravenous infusion, large numbers of GFP-MSCs lodged in lungs and intestines while small numbers in the liver, spleen and kidney.CONCLUSIONS:MSCs has no effect on proliferation but induce apoptosis of allo-reactive T cells; MSCs can inhibit the second activation of allogeneic T cells, significantly reduce the secretion of IFN-gamma and TNF-alpha; MSCs might be able to repair GVHD target tissues by extensive distribution to lungs, intestines, and liver of the animals.

Reduction in Murine Acute GVHD Severity by Human Gingival Tissue-Derived Mesenchymal Stem Cells Via the CD39 Pathways

Human Gingival Tissue-Derived Mesenchymal Stem Cells Inhibit Proliferation and Invasion of Rheumatoid Fibroblast-Like Synoviocytes Via the CD39/CD73 Signaling Pathway

Human Gingiva-Derived Mesenchymal Stem Cells Inhibit Xeno-Graft-Versus-Host Disease Via Cd39-Cd73-Adenosine and Ido Signals

Human Gingiva-Derived Mesenchymal Stromal Cells Inhibit Graft-Versus-Host Disease Through CD39 and IDO.

Human gingiva-derived mesenchymal stromal cells inhibit graft-versus-host disease through CD39 and IDO (THER5P.844)

Human gingiva tissue-derived MSC ameliorates immune-mediated bone marrow failure of aplastic anemia via suppression of Th1 and Th17 cells and enhancement of CD4+Foxp3+ regulatory T cells differentiation

CXCR4-transduced Mesenchymal Stem Cells Protect Mice Against Graft-Versus-host Disease.

Experimental Research on Inhibition of Acute Graft-versus -Host Disease by Transplanted Mesenchymal Stem Cells in Murine Model

Gingiva-derived Mesenchymal Stem Cells-Mediated Therapeutic Intervention for Experimental Arthritis Through Foxp3+ Tregs (56.7)

[The Role of Marrow Derived Mesenchymal Stem Cells in the Prevention and Treatment of Acute Graft-Versus-host in Mice.].

Transplanted Mesenchymal Stem Cells Can Inhibit the Three Developmental Stages of Murine Acute Graft-Versus-Host Disease

Mesenchymal Stem Cells ameliorate Chronic GVHD by Boosting Thymic Regeneration in a CCR9-dependent manner in mice

Human GMSCs Treat Murine Model with Aplastic Anemia Through Regulating the Balance Between Treg and Th17 Cells

Mesenchymal Stromal Cells Ameliorate Chronic GVHD by Boosting Thymic Regeneration in a CCR9-dependent Manner in Mice.

Enhanced Alleviation of Agvhd by TGF‐β1‐modified Mesenchymal Stem Cells in Mice Through Shifting MΦ into M2 Phenotype and Promoting the Differentiation of Treg Cells

A Preclinical Studysystemic Evaluation of Safety on Mesenchymal Stem Cells Derived from Human Gingiva Tissue

Updates on GMSCs treatment for autoimmune diseases.

Human Gingiva-Derived Mesenchymal Stem Cells Alleviate Inflammatory Bowel Disease via IL-10 Signaling-Dependent Modulation of Immune Cells.

A preclinical study—systemic evaluation of safety on mesenchymal stem cells derived from human gingiva tissue

Single-cell analysis of immune cells on gingiva-derived mesenchymal stem cells in experimental autoimmune uveitis

hUC-MSCs Attenuate Acute Graft-Versus-Host Disease through Chi3l1 Repression of Th17 Differentiation.